Zobrazeno 1 - 10
of 40
pro vyhledávání: ''
Autor:
Charles Jeng Chen, Terrence Bradley, Helena G. Dos Santos, Ronan T. Swords, Luisa Cimmino, Yvonne Trang Dinh, Ramin Shiekhattar, Artur Zelent, Justin M. Watts, Aymee Perez, Deukwoo Kwon, Mina Masoumeh Tayari, Amber Thomassen, Lluis Morey
Publikováno v:
Clin Cancer Res
Purpose: In preclinical studies, the lysine-specific histone demethylase 1A (LSD1) inhibitor tranylcypromine (TCP) combined with all-trans retinoic acid (ATRA) induces differentiation and impairs survival of myeloid blasts in non-acute promyelocytic
Autor:
Judy S. Wang, Aimee Bence Lin, Wenjuan Wu, Kathleen N. Moore, Xuejing Aimee Wang, Gregory P. Donoho, Susanna Varkey Ulahannan, Manish R. Patel, Suzanne F. Jones, Johanna C. Bendell, Daniel D. Karp, Andrew Capen, David S. Hong, Yan Ding
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(7)
Purpose:Prexasertib, a checkpoint kinase 1 inhibitor (CHK1), exhibited modest monotherapy antitumor activity in previous studies. Preclinical data were generated to support the clinical combination of prexasertib + samotolisib, a PI3K/mTOR inhibitor.
Autor:
Julie Roques, Patricia Santofimia-Castaño, Analía Meilerman Abuelafia, Odile Gayet, Emmanuel Telle, Juan L. Iovanna, Nicolas A. Fraunhoffer, Maria Teresa Borrello, Nelson Dusetti, Martin Bigonnet, Eduardo Chuluyan
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient prognosis; however, the clinical efficacy of these treatments is low. One of th
Autor:
Chaoyun Pan, JiHoon Kang, Yu Zhang, Anna Umano, Wenqing Yang, Sumin Kang, Lingtao Jin, Kelly R. Magliocca, Austin C. Boese, Sagar Lonial, Jie Li
Publikováno v:
Clin Cancer Res
Purpose: Although platinum compounds are the first-line treatment for ovarian cancer, the majority of patients relapse and develop resistance to treatment. However, the mechanism underlying resistance is unclear. The goal of our study is to decipher
Autor:
Aaron T. Scott, Po Hien Ear, Shaikamjad Umesalma, Patrick Breheny, Chandrikha Chandrasekharan, Courtney A. Kaemmer, Michelle Weitz, Thomas M. O'Dorisio, Joseph S. Dillon, Benjamin W. Darbro, Bartley Brown, Andrew M. Bellizzi, Dawn E. Quelle, Chandra K. Maharjan, Terry A. Braun, James R. Howe, Guiying Li
Publikováno v:
Clin Cancer Res
Purpose: Pancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past decades,
Autor:
Masato Kobayashi, Kiyoshi Ariizumi, Ponciano D. Cruz, Song Zhang, Vijay Ramani, Vinita Popat, Farjana J. Fattah, David E. Gerber, Jin Sung Chung
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(6)
Purpose: Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification of biomarkers distinguishing responders and nonresponders will improve management of patients with cancer. Because the DC-HIL checkpoi
Autor:
François Vaillant, Jane E. Visvader, Antonia N. Policheni, Huiling Xu, Hans Clevers, Daniel H.D. Gray, Andrew Fellowes, Göknur Giner, Bianca D. Capaldo, Thomas Green, Stephen B. Fox, Geoffrey J. Lindeman, Norman Sachs, James R. Whittle, He K. Liu, Johanna F. Dekkers, Huei-Rong Chen, Elliot Surgenor, Gordon K. Smyth, Marco J Herold
Publikováno v:
Clinical Cancer Research, 26(15), 4120-4134. American Association for Cancer Research Inc.
Purpose: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metastatic estrogen receptor–positive (ER+) breast cancer, relapse is almost inevitable. This may, in part, reflect the failu
Autor:
Jessie Hou, Sandrine Puverel, Stephen J. Forman, Yuming Guo, Matthew Mei, Wing C. Chan, Xiwei Wu, Vu N. Ngo, Joo Y. Song, Shu Tao, Shuhua Yi, Timothy W. Synold, Larry W. Kwak, Lu Chen, Jun Wu, Alex F. Herrera, Leslie Popplewell, Edward M. Newman, Steven T. Rosen, Robert T. Chen
Publikováno v:
Clin Cancer Res
Purpose: In classical Hodgkin lymphoma, the malignant Reed–Sternberg cells express the cell surface marker CD30. Brentuximab vedotin is an antibody–drug conjugate (ADC) that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(20)
Purpose: The resistance to differentiation therapy and early death caused by fatal bleeding endangers the health of a significant proportion of patients with acute promyelocytic leukemia (APL). This study aims to investigate the molecular mechanisms
Autor:
Lin Bao, Xiaoping Zhang, Zhiyong Xiong, Qi Cao, Cheng Wang, Tianbo Xu, Wen Xiao, Di Liu, Hailong Ruan, Diwei Zhou, Ming Yang, Gong Cheng, Hongmei Yang, Keshan Wang, Zhengshuai Song, Ke Chen, Xiong Yang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(6)
Purpose: Emerging evidence indicates that castration-resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor (AR) or its V7 splice variant (AR-V7) and commonly becomes resistant to endocrine therapy. The aim of thi